STRO Valuation

Sutro Biopharma Inc

Add to Watchlist

Advanced Chart

0.887

-0.028(-3.060%)1D

Overview
Forecast
Valuation
Earnings

STRO Relative Valuation

STRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, STRO is overvalued; if below, it's undervalued.

Historical Valuation

Sutro Biopharma Inc (STRO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.36 is considered Undervalued compared with the five-year average of -3.31. The fair price of Sutro Biopharma Inc (STRO) is between 3.34 to 11.07 according to relative valuation methord. Compared to the current price of 0.89 USD , Sutro Biopharma Inc is Undervalued By 73.42%.

Relative Value

Fair Zone

3.34-11.07

Current Price：0.89

73.42%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-2.99

P/B

Median3y

1.42

Median5y

1.81

-271.90

FCF Yield

Median3y

-65.32

Median5y

-45.91

Competitors Valuation Multiple

The average P/S ratio for STRO's competitors is 15.73, providing a benchmark for relative valuation. Sutro Biopharma Inc Corp (STRO) exhibits a P/S ratio of 1.28, which is -91.86% above the industry average. Given its robust revenue growth of 33.76%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap